Ideaya Biosciences (IDYA)

Trade IDYA now with
4/16/2021 6:04:05 AM IDEAYA Reports Darovasertib Monotherapy OS Data; Observes Early Partial Responses In Binimetinib Combination In MUM
4/15/2021 6:01:57 AM IDEAYA Announces Doses First Patient Of MAT2A Inhibitor IDE397 In Phase 1 Clinical Trial Of MTAP-Deletion Solid Tumors
3/23/2021 6:08:11 AM IDEAYA Announces Dose Expansion Of Phase 1/2 Study Of Combination Of IDE196 And Binimetinib In Metastatic Uveal Melanoma
3/23/2021 6:07:55 AM IDEAYA Biosciences Q4 Net Loss $5.1 Mln Vs. Net Loss $10.8 Mln Last Year
3/11/2021 6:07:57 AM IDEAYA Announces Presentations At AACR For Synthetic Lethality Programs IDE397 And PARG, And Kinase Inhibitor IDE196
2/8/2021 6:04:30 AM IDEAYA Targets First-Patient-In For IDE397 Phase 1 Study In Q1
1/19/2021 6:02:32 AM Spelman College, IDEAYA Partner For Professional Development Of Next Generation Of Female African American Leaders
1/11/2021 6:03:00 AM IDEAYA Biosciences Submits IND Application For MAT2A Development Candidate IDE397 With The U.S. FDA
1/5/2021 6:06:14 AM IDEAYA Biosciences Doses First Patient In A Phase 1 Combination Study Of IDE196 And Crizotinib
12/14/2020 6:01:28 AM IDEAYA Biosciences Announces Addition To NASDAQ Biotechnology Index
11/12/2020 6:04:49 AM IDEAYA Biosciences Q3 Loss Per Share $0.17 Vs Loss $0.54 Last Year
9/24/2020 6:01:26 AM IDEAYA Biosciences Expands Clinical Trial Collaboration And Supply Agreement With Pfizer
8/12/2020 6:03:24 AM IDEAYA Biosciences Q2 Loss Per Share $0.59 Vs Loss $1.30 Last Year